Jury Awards $6.5 Million in First Actos Bladder Cancer Lawsuit
A California jury in late April returned a $6.5 million verdict in the first case to go to trial over the link between the diabetes drug Actos and bladder cancer. Actos maker Takeda Pharmaceuticals currently faces thousands of pending lawsuits in multiple states.
The jury in the first Actos trial found that Takeda Pharmaceuticals failed to provide adequate warnings to physicians and patients about the dangers of Actos and that this negligence was a factor in the plaintiff developing terminal bladder cancer. During the trial, the jury was presented with evidence that Takeda knew of the link between Actos and bladder cancer in 2004, but did not disclose that association to the U.S. Food and Drug Administration (FDA) for nearly another seven years.
Despite the verdict in the first Actos trial and the mounting number of lawsuits, Takeda continues to deny liability and is said to be considering an appeal. Actos remains on the market, although the FDA in 2011 issued a drug safety alert for Actos that warns patients who use Actos for more than one year may face an increased risk for bladder cancer.
For additional information on dangerous prescription medications, please see our Pharmaceutical Injuries page.